Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

Findings were published today in The Lancet Diabetes & Endocrinology. Originally developed to treat diabetes, GLP-1 receptor agonists mimic the action of a hormone called glucagon-like peptide 1, ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

A long-term study suggests GLP-1 agonists, especially semaglutide ... potentially mediated by dopamine modulation in reward mechanisms. Furthermore, genetic associations between GLP-1 receptors ...

“HEC88473 is one of Sunshine Lake’s very first novel biologics programs, showcasing strong therapeutic potential with its differentiated mechanism of action ... GLP-1/FGF21 Dual Agonist ...

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists. The phase 2 ELAD study of Novo ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

Ω * The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, the MindBody GLP-1 System could holistically and sustainably ...